Drug Trial Radar · NCT06221683
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Last checked: Nov 20, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jan 1, 2024
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Children's Hospital of Soochow UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.
Conditions
- AML, Childhood
- Acute Myeloid Leukemia
Interventions
HomoharringtonineDrug
3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours
CytarabineDrug
100mg/m2/q12h for weighing \>10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing \>10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;
EtoposideDrug
100mg/m2/d for weighing \>10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
VenetoclaxDrug
100mg/m2/d for weighing \>10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd
Mitoxantrone hydrochloride liposomeDrug
5mg/m2/d for weighing \>10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
Recombinant Human Granulocyte Colony-Stimulating FactorDrug
5ug/kg/d, d1-10, s.c., qd, at 1pm
Idarubicin HydrochlorideDrug
3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.
SorafenibDrug
100mg/m2/day for weighing \>10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd
GilteritinibDrug
20mg/m2/day for weighing \>10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd
AvapritinibDrug
50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of CR/CRi with negative MRDTime frame: Day 26 (HAE group) and Day 32 (MAG+Ven group) for remission induction 1 and 2 are the necessary time points for response evaluation.
- Event-free survivalTime frame: From date of treatment until the date of the occurrence of the event, whichever comes first, assessed up to 72 months. Patients remaining event-free are censored at the last follow-up time.
- Cumulative incidence of relapseTime frame: From date of treatment until the date of when a failure of CIR occurs, whichever comes first, assessed up to 72 months.
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Beijing Institute of Genomics, Chinese Academy of Sciences
Beijing, China · Not yet recruiting
First Affiliated Hospital Of University of Science and Technology of China
Hefei, Anhui, China · Not yet recruiting
The Second Hospital of Anhui Medical University
Hefei, Anhui, China · Not yet recruiting
Guangzhou Women and Children Medical Center
Guangzhou, Guangdong, China · Not yet recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
Kaifeng Children's Hospital
Kaifeng, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
XiangYa Hospital Central South University
Changsha, Hunan, China · Not yet recruiting
Children's Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Xuzhou Children's Hospital
Xuzhou, Jiangsu, China · Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Not yet recruiting
Children's Hospital Of Fudan University
Shanghai, Shanghai Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.